Viewing Study NCT07047118

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:46 AM
Ignite Modification Date: 2026-03-06 @ 10:10 PM
Study NCT ID: NCT07047118
Status: RECRUITING
Last Update Posted: 2025-12-03
First Post: 2025-05-20
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Prostatic Cancer, Castration-Resistant View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Prostate cancer View
None metastatic Castration Resistant Prostate Cancer (mCRPC) View
None Castration-resistant View
None Prostate-Specific Membrane Antigen (PSMA) View
None PSMA-positive View
None Radioligand Therapy (RLT) View
None lutetium (177Lu) vipivotide tetraxetan View
None Phase 2 View
None Open-label View
None Androgen Receptor Pathway Inhibitor (ARPI) View